BPC
MLTX icon

Banque Pictet & Cie’s MoonLake Immunotherapeutics MLTX Stock Holding History

Banque Pictet & Cie’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-640,000
Closed -$32.6M – 494
2023
Q2 		$32.6M Buy
+640,000
New +$17.2M 0.29% 52

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Banque Pictet & Cie's MLTX Position: Q3 2023 in Review

Banque Pictet & Cie sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2023, closing a stake of 640,000 shares — an estimated $32.6M sold.

Banque Pictet & Cie first reported a position in MLTX in Q2 2023 and held it in 1 quarter. The position peaked at $32.6M in Q2 2023. 118 funds tracked by Wall St. Rank hold MLTX as of Q3 2023.

  • Banque Pictet & Cie reported no remaining MoonLake Immunotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Banque Pictet & Cie sold 640,000 MoonLake Immunotherapeutics shares in Q3 2023, an estimated $32.6M.
  • Banque Pictet & Cie first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 1 quarter.
  • Banque Pictet & Cie's MoonLake Immunotherapeutics position peaked at $32.6M in Q2 2023.
  • 118 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2023.

Based on Banque Pictet & Cie's 13F filing for Q3 2023, filed 2 Nov 2023.